CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended				80 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013
Revenue	$ 0		$ 0		$ 0
Operating expense
Research and development	1,518,885	[1]	1,132,712	[1]	5,844,481	[1]
General & administrative	1,634,650	[2]	986,097	[2]	8,694,113	[2]
Total operating expense	3,269,240		2,582,679		15,717,919
Net operating loss	(3,269,240)		(2,582,679)		(15,717,919)
Other income (expense)
Interest income	4,037		779		81,127
Other income	0		0		244,479
Other expense	(810)		(637)		(4,983)
Total Other Income (Expense)	3,227		142		320,623
Net Loss Before Income Taxes	(3,266,013)		(2,582,537)		(15,397,296)
Income tax expense	0		0		0
Net Loss	(3,266,013)		(2,582,537)		(15,397,296)
Loss per share
Net loss per share, basic and diluted	$ (0.05)		$ (0.04)		$ (0.31)
Basic and diluted weighted average number of common shares outstanding	71,372,672		59,317,779		49,844,257
Related Party
Operating expense
Research and development	$ 115,705	[3]	$ 463,870	[3]	$ 1,179,325	[3]

[1] Research and development expense includes stock option expense of $32,879 and $53,645 for the years ending 12/31/2013 and 12/31/2012, respectively; and $455,877 for the period from inception through 12/31/2013. Research and development expense also includes amortization expense of $160,625 and $185,271 for the years ending 12/31/2013 and 12/31/2012, respectively; and $1,137,359 for the period from inception through 12/31/2013.

[2] General & administrative expense includes stock option expense of $671,601 and $9,740 for the years ending 12/31/2013 and 12/31/2012, respectively; and for the period from inception through 12/31/2013, $3,262,356 for stock option and warrant expense and $318,500 in stock for services.

[3] Includes $345,000 technology impairment charge for the year ending 12/31/2012; and technology impairment of $690,000 for the period from inception through 12/31/2013.